SLC30A10 and Cirrhosis: This function thus identifies SLC39A8 as a candidate therapeutic target for the prevention/mitigation of brain Mn accumulation, such as for patients with genetic disorders that cause brain Mn accumulation (e.g., loss-of-function mutations in SLC30A10 (14, 15) or SLC39A14 (16)) or patients with chronic liver disease (e.g., cirrhosis) that can result in neurotoxic accumulation of brain Mn (58).